Navigation Links
DATATRAK Awarded First Study With Kreara Solutions

CLEVELAND, March 8, 2011 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded its first study by Kreara Solutions, a Contract Research Organization (CRO) in India, with which the Company had partnered in 2010. Both companies will work together in order to execute a Phase II study for the Dermatology Division of a Global Enterprise, whose core competencies include the fields of Health Care, Nutrition and High-Tech Materials.  

The trial will be conducted in Japan and employ several CROs based in Japan, India and the USA to conduct project management, monitoring, data management and other study-specific services. All of the CROs, as well as the Sponsor, will be utilizing DATATRAK eClinical™ for Electronic Data Capture (EDC) and Medical Coding.

Anoop P. Ambika, Kreara's CEO and Managing Director said, "Kreara has always strived to provide quality and timely data management services to its clients in adherence to the internal standards and standards set by the client and regulatory bodies. Kreara looks forward to working closely with DATATRAK to deliver the challenging requirements of this trial, all the while adhering to the cost, quality and timeliness as envisioned during the planning phase."

"DATATRAK's unified eClinical platform is an ideal solution for studies which intend to employ multiple CROs from various geographic locations around the world," said Laurence P. Birch, DATATRAK's Chairman and CEO.  "We can help companies to streamline their study communications, provide a single point of access for all study users, and enable both the Sponsor and CROs to gain real-time access to patient data. We are excited to embark on this first study with Kreara, especially as we guide them through the design and deployment of their study as an Enterprise Transfer client."

About Kreara Solutions

KREARA Solutions is a clinical data management and biometrics solution provider based out of the beautiful campus of Technopark Trivandrum, Kerala in India. Kreara was established in April 2004 as a private limited company with the intention of providing quality services for the clinical research, life sciences and financial markets. Kreara has grown into a leading Clinical Research Organization that specializes in providing data management, statistical and software solutions for the process of clinical drug development. Having grown into one of the most trusted partners for some of the life sciences companies across the globe, Kreara has worked with clients from Europe, USA and Japan. For more information on Kreara, please visit

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 67 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the Pink OTC Markets on November 12, 2010 announcing its results for the three-month period ending September 30, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
2. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
3. DATATRAK International Reports First Quarter Results for 2008
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
6. DATATRAK eClinical(TM) Supports Multifaceted Studies
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK Signs 6 Year Study with New Device Client
9. DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
10. DATATRAK International, Inc. Announces Year-End Backlog
11. DATATRAK Signs Five-Year Registry Study
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):